oral

vVARDIS Drill-Free Solution Curodont Has Treated Over One Million Teeth in 18 Months and Is the Fastest Growing Dental Care Product in Its Category

Clinical adoption of Curodont™ is helping to elevate the standard of care in caries management Leading clinical experts herald Curodont™…

2 days ago

Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo) for Skin Health

SHELTON, Conn., July 06, 2025 (GLOBE NEWSWIRE) -- Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut,…

3 weeks ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

3 weeks ago

Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions

Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. Preclinical…

1 month ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 19:30 ET  | Source: Structure Therapeutics Inc. SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics…

1 month ago

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 16:52 ET  | Source: Vaxart, Inc. SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart,…

1 month ago

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial…

1 month ago

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

June 06, 2025 16:07 ET  | Source: Restem MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology…

2 months ago

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare…

2 months ago

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)…

2 months ago